Wilson Sonsini is a proud sponsor of the 2nd BCLT Advanced Life Sciences Institute and a founding member of the Life Sciences Law & Policy Center.
Rapid advancement in life sciences technologies has made keeping up with the legal implications more important than ever. Join us for the 2nd BCLT Advanced Life Sciences Institute, where you will learn from the experts about cutting-edge issues impacting your life sciences practice.
Our programming will share key insights and best practices related to the rapid rise of AI in the life sciences, privacy law updates, and new trends for licensing, deals, and funding models. We will also have experts reviewing key developments in the law (Section 112, obviousness-type double patenting), anti-counterfeiting and patient safety, and the ever-complex interplay of regulatory and IP exclusivities.
Finally, don’t miss our in-depth discussions on current events in genomics disputes, future pandemic preparedness, use of trade secrets v. patents for portfolio protection, and ongoing debates in drug pricing (march-in rights, the Inflation Reduction Act, and more!)
The Advanced Life Sciences Institute will be launched virtually through B-CLE on May 21 and 22. You do not want to miss this special event!
Registration is free and available to all, and CLE will be offered.
About B-CLE
Enrollment and CLE are complimentary. A B-CLE account is required to enroll for courses. Subscribe at no charge.
B-CLE is only certified to give credit for California. If you are seeking credit for another jurisdiction, please check with your state bar to determine if California CLE credits are recognized, through reciprocity, in your jurisdiction.
Norilyn Ingram
ningram@wsgr.comVern has three decades of experience formulating successful strategies for innovative life science companies and helping them develop IP programs.
Eva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.